Dyax Announces Treatment of First Patient in Phase 2 Trial of Ecallantide for Acute Treatment of ACE Inhibitor-Induced Angioedema

Dyax Corp. DYAX announced today treatment of the first patient in a Phase 2 trial evaluating the efficacy and safety of ecallantide, a potent, selective, reversible inhibitor of plasma kallikrein, for acute treatment of angiotensin converting enzyme inhibitor-induced angioedema. This form of angioedema, or rapid swelling of the dermis, mucosa or other tissues, most commonly occurs in the head, face and tongue, and can be severe or life threatening. Ecallantide is approved under the brand name KALBITOR® in the United States for the treatment of acute attacks of hereditary angioedema in patients 16 years of age and older.